Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) has taken a decisive step to expand its operational capabilities. The company recently announced the acquisition of the Additive Manufacturing Electronics (AME) platform from Nano Dimension Ltd. (Nasdaq: NNDM). This strategic move transfers a comprehensive suite of high-precision manufacturing assets to Inspira, positioning the company for a new phase of strategic growth.
This transaction represents a significant transition for Inspira. By securing control over advanced manufacturing infrastructure, the company broadens its technological footprint beyond its core medical device portfolio. This article examines the financial structure of the deal, the specific capabilities of the AME platform, and how this acquisition aligns with Inspira’s long-term corporate strategy.
The Financial Framework of the Acquisition
The acquisition involves a structured financial agreement valued at up to $12.5 million. Inspira executed a $2.0 million upfront cash payment to initiate the transfer of assets. The remaining $10.5 million consists of deferred payments. These future disbursements are strictly tied to the performance metrics of the AME platform over the next twelve months.
This performance-based structure mitigates immediate financial risk while ensuring the newly acquired assets deliver verifiable value. Consequently, Inspira assumes immediate control of the operations while awaiting standard regulatory approvals to finalize the transaction.
The scope of the acquired assets provides Inspira with a fully functional operational base. The transaction includes:
- Proprietary high-precision 3D electronic printing systems
- Patented software and specialized engineering know-how
- Manufacturing equipment and existing inventory
- Customer-related assets
- Fully equipped physics and chemistry laboratories
- An operational ink manufacturing plant
By absorbing these resources, Inspira gains immediate access to a turnkey advanced manufacturing ecosystem.
Decoding the AME Technology Platform
The AME technology serves as a highly advanced, multi-material additive manufacturing system. It specifically excels at printing 3D electronic layers with extraordinary micro-scale precision. Additive manufacturing electronics represent a critical evolution in industrial production, allowing developers to integrate materials seamlessly and build complex architectures that traditional manufacturing methods often cannot achieve.
Furthermore, this platform consistently delivers robust performance under demanding operating conditions. Engineers utilize this technology to develop next-generation, high-value electronic applications. By acquiring this system, Inspira integrates specialized engineering expertise that drives innovation in highly customized, low-volume manufacturing sectors.
Nano Dimension originally developed these technologies to support critical industries, including defense, aerospace, automotive, and medical devices. Now, Inspira controls this intellectual property, unlocking new avenues for technological deployment.
Strategic Realignment and Future Operations
Inspira Chief Executive Officer Dagi Ben-Noon emphasized the immediate operational advantages of the acquisition. According to Ben-Noon, the AME technology provides Inspira with a highly specialized manufacturing platform backed by proven infrastructure and deep engineering capabilities. The company plans to direct these assets toward high-value applications that complement its evolving corporate strategy.
To accommodate this broader technological focus, Inspira is actively restructuring its internal operations. The company will transfer its existing medical business activities into a wholly owned subsidiary. This structural shift ensures that its core medical operations continue independently. Management confirmed that the company will not sell, discontinue, or replace its existing medical initiatives as a result of the AME acquisition.
Impact on Inspira’s Current Product Portfolio
Inspira Technologies has established a strong foundation as a commercial-stage medical device company. The organization specializes in advanced respiratory support and real-time blood monitoring solutions. Its flagship product, the FDA-cleared INSPIRA ART100 system, currently supports cardiopulmonary bypass procedures in the United States and Extracorporeal Membrane Oxygenation (ECMO) procedures internationally.
Additionally, Inspira continues to develop the INSPIRA ART500, a next-generation system designed to deliver oxygenation to awake, spontaneously breathing patients. Concurrently, the company is advancing the HYLA platform, a proprietary blood sensor technology focused on continuous, non-invasive monitoring.
While these life-support and MedTech innovations remain central to the new subsidiary’s mission, the AME acquisition introduces a powerful new dimension to the parent company. Access to high-precision 3D electronic printing and advanced chemistry laboratories could potentially accelerate research and development timelines across the board.
Looking Ahead: A Transformed Corporate Trajectory
The integration of Nano Dimension’s AME platform marks a pivotal transformation for Inspira Technologies. By securing cutting-edge intellectual property, physical laboratories, and specialized manufacturing equipment, the company diversifies its operational capabilities significantly.
Inspira management intends to release an additional strategic update shortly. Industry analysts and stakeholders will monitor this upcoming announcement to understand exactly how the company plans to synthesize its expanded manufacturing prowess with its established medical device operations. Ultimately, this acquisition strengthens Inspira’s intellectual property portfolio and positions the organization to capitalize on emerging opportunities in advanced manufacturing and complex electronic integration.
About Inspira Technologies
Inspira Technologies is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions. The Company’s FDA-cleared INSPIRA™ ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO (Extracorporeal Membrane Oxygenation) procedures outside the U.S and serves as a foundation for the development of the INSPIRA ART500, a next-generation system designed to deliver oxygenation while patients remain awake and spontaneously breathing. Inspira Technologies is also advancing HYLA™, a proprietary blood sensor platform offering continuous, non-invasive monitoring. With multiple cleared products, a growing IP portfolio, and strategic streamlining of its operations, Inspira Technologies is increasingly positioned as an attractive platform within the life-support and MedTech landscape. For more information, visit: https://inspira-technologies.com
About Nano Dimension Ltd.
Driven by strong trends in onshoring, national security, and increasing product customization, Nano Dimension Ltd. (Nasdaq: NNDM) delivers advanced Digital Manufacturing technologies to the defense, aerospace, automotive, electronics, and medical devices industries, enabling rapid deployment of high-mix, low-volume production with IP security and sustainable manufacturing practices. For more information, please visit https://www.nano-di.com/
The post Inspira Technologies Acquires Nano Dimension’s AME Platform appeared first on PRISM MarketView.